A detailed history of High Tower Advisors, LLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, High Tower Advisors, LLC holds 115,790 shares of ALNY stock, worth $27.3 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
115,790
Previous 125,041 7.4%
Holding current value
$27.3 Million
Previous $30.4 Million 4.83%
% of portfolio
0.05%
Previous 0.05%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$233.81 - $287.01 $2.16 Million - $2.66 Million
-9,251 Reduced 7.4%
115,790 $31.9 Million
Q2 2024

Aug 13, 2024

SELL
$143.31 - $247.0 $148,899 - $256,633
-1,039 Reduced 0.82%
125,041 $30.4 Million
Q1 2024

May 06, 2024

BUY
$146.51 - $198.2 $272,508 - $368,652
1,860 Added 1.5%
126,080 $18.8 Million
Q4 2023

Feb 12, 2024

SELL
$151.41 - $196.57 $33,158 - $43,048
-219 Reduced 0.18%
124,220 $23.8 Million
Q3 2023

Nov 08, 2023

SELL
$170.77 - $211.65 $230,027 - $285,092
-1,347 Reduced 1.07%
124,439 $22 Million
Q2 2023

Aug 14, 2023

BUY
$185.01 - $212.05 $41,812 - $47,923
226 Added 0.18%
125,786 $23.9 Million
Q1 2023

May 11, 2023

SELL
$182.66 - $235.53 $33,244 - $42,866
-182 Reduced 0.14%
125,560 $25.2 Million
Q4 2022

Feb 08, 2023

SELL
$185.53 - $241.31 $208,164 - $270,749
-1,122 Reduced 0.88%
125,742 $29.9 Million
Q3 2022

Nov 09, 2022

SELL
$138.54 - $232.0 $614,840 - $1.03 Million
-4,438 Reduced 3.38%
126,864 $25.4 Million
Q2 2022

Aug 10, 2022

SELL
$120.42 - $169.29 $407,862 - $573,385
-3,387 Reduced 2.51%
131,302 $19.1 Million
Q1 2022

May 12, 2022

BUY
$127.18 - $173.91 $640,478 - $875,810
5,036 Added 3.88%
134,689 $22 Million
Q4 2021

Feb 10, 2022

BUY
$159.56 - $209.29 $19.6 Million - $25.7 Million
123,016 Added 1853.49%
129,653 $22 Million
Q3 2021

Nov 12, 2021

BUY
$169.75 - $207.73 $7,129 - $8,724
42 Added 0.64%
6,637 $1.26 Million
Q2 2021

Aug 06, 2021

SELL
$128.63 - $176.89 $10,033 - $13,797
-78 Reduced 1.17%
6,595 $1.12 Million
Q1 2021

May 10, 2021

BUY
$126.83 - $175.69 $101,337 - $140,376
799 Added 13.6%
6,673 $937,000
Q4 2020

Feb 10, 2021

SELL
$122.97 - $147.0 $13,895 - $16,611
-113 Reduced 1.89%
5,874 $761,000
Q3 2020

Nov 13, 2020

SELL
$121.19 - $165.49 $20,117 - $27,471
-166 Reduced 2.7%
5,987 $872,000
Q2 2020

Aug 10, 2020

SELL
$104.21 - $156.44 $208 - $312
-2 Reduced 0.03%
6,153 $913,000
Q1 2020

May 21, 2020

SELL
$93.12 - $133.99 $372 - $535
-4 Reduced 0.06%
6,155 $677,000
Q4 2019

Feb 14, 2020

BUY
$74.51 - $124.23 $19,000 - $31,678
255 Added 4.32%
6,159 $711,000
Q3 2019

Nov 12, 2019

BUY
$70.9 - $87.82 $14,534 - $18,003
205 Added 3.6%
5,904 $473,000
Q2 2019

Aug 13, 2019

SELL
$65.86 - $92.79 $42,479 - $59,849
-645 Reduced 10.17%
5,699 $417,000
Q4 2018

Feb 14, 2019

SELL
$62.67 - $88.33 $3,133 - $4,416
-50 Reduced 0.78%
6,344 $463,000
Q3 2018

Nov 09, 2018

BUY
$87.52 - $122.67 $559,602 - $784,351
6,394 New
6,394 $564,000
Q3 2017

Nov 14, 2017

SELL
$72.53 - $118.27 $282,867 - $461,253
-3,900 Closed
0 $0
Q2 2017

Aug 14, 2017

BUY
N/A
3,900
3,900 $311,000

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $29B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track High Tower Advisors, LLC Portfolio

Follow High Tower Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of High Tower Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on High Tower Advisors, LLC with notifications on news.